平目汤2号对非活动期Graves眼病相关指标的影响

Effects of Pingmu Decoction-Ⅱ on the laboratory indicators related to the non-active Graves' ophthalmopathy

关键词:  非活动期  Graves眼病  平目汤2号  泼尼松

Key words:  non-active  Graves' ophthalmopathy  Pingmu Decoction-Ⅱ  prednisone

摘要:

[目的]观察平目汤2号对非活动期Graves病浸润性突眼治疗前后相关检查指标的影响。[方法]将65例非活动期Graves眼病的患者随机分为试验组34例和对照组31例，采取双盲双模拟的方法，试验组服用"平目汤2号"及西药泼尼松模拟剂，对照组服用泼尼松及"平目汤2号"模拟剂。疗程均为12周。观察血液流变学指标、CD3⁺、CD4⁺、CD8⁺、CD4⁺/CD8⁺等治疗前后的变化，并观察任何可能出现的不良反应。[结果]试验组可有效改善非活动期Graves眼病患者的血液流变学指标（P<0.01）。CD3⁺、CD4⁺、CD8⁺、CD4⁺/CD8⁺治疗前后无明显变化。试验组不良反应发生率低于对照组（P<0.05）。[结论]"平目汤2号"可有效改善非活动期Graves眼病患者的血液流变学指标，安全性高，不良反应少。

Abstract:

[Objective] To observe the changes of laboratory indicators related to the non-active Graves' ophthalmopathy before and after using Pingmu Decoction-Ⅱ.[Methods] The 65 cases who have the Non-active Graves' ophthalmopathy were randomly divided into treatment group (n=34) and control group (n=31) in a double-blind, double-dummy, randomized-controlled trial. The treatment group received "Pingmu Decoction-Ⅱ" and a placebo for prednisone, and the patients in control group were treated with prednisone and a placebo for "Pingmu Decoction-Ⅱ", with a course of twelve weeks. Then observe the changes of hemodynamic indexes, CD3⁺, CD4⁺, CD8⁺, CD4⁺/CD8⁺ before and after the treatment, and all the treatment adverse reactions.[Results] The experimental group can effectively ameliorating the hemodynamic indexes of the patients with Non-active Graves' ophthalmopathy (P<0.01). But it has no significant changes on CD3⁺, CD4⁺, CD8⁺, CD4⁺/CD8⁺ before and after the treatment. The adverse reaction rates of experimental group were less than control group (P<0.05).[Conclusion] "Pingmu Decoction-Ⅱ" can effectively ameliorating the hemodynamic indexes of the patients with non-active Graves' ophthalmopathy, and it has more safety and less adverse reaction.